Our findings provide evidence that the SF3B4-KLF16-Twist1 axis plays important functional roles in the development and progression of ccRCC, and manipulating this pathway may be a novel therapeutic target for the treatment of ccRCC. This evidence concerns the gene SF3B4 and nonpapillary renal cell carcinoma.